Sector
PharmaceuticalsOpen
₹1,283.6Prev. Close
₹1,275.2Turnover(Lac.)
₹58,234.92Day's High
₹1,293Day's Low
₹1,269.252 Week's High
₹1,405.952 Week's Low
₹1,020Book Value
₹385.87Face Value
₹1Mkt Cap (₹ Cr.)
1,06,748.05P/E
19.73EPS
64.68Divi. Yield
0.63No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 83.4 | 83.4 | -43.6 | -76.9 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 28,773.2 | 24,157.4 | 20,517.8 | 18,413.1 |
Net Worth | 28,856.6 | 24,240.8 | 20,474.2 | 18,336.2 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 14,405.2 | 13,349.1 | 11,850.4 | 9,359.3 |
yoy growth (%) | 7.91 | 12.64 | 26.61 | -3.7 |
Raw materials | -5,045.9 | -4,123 | -3,573.8 | -2,631 |
As % of sales | 35.02 | 30.88 | 30.15 | 28.11 |
Employee costs | -2,434.6 | -2,270.1 | -2,030.2 | -1,843 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 2,223.8 | 3,056.2 | 2,775.8 | 696.99 |
Depreciation | -814.3 | -835 | -789.2 | -774.1 |
Tax paid | -600.6 | -869.8 | 161.9 | -130.1 |
Working capital | 1,395.8 | 1,078.3 | 508.8 | -170.1 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 7.91 | 12.64 | 26.61 | -3.7 |
Op profit growth | -17.3 | 9.31 | 115.77 | -23.81 |
EBIT growth | -27.1 | 9.89 | 271.62 | -52.56 |
Net profit growth | -25.75 | -25.57 | 418.2 | -59.04 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 32,553.5 | 27,916.4 | 24,587.9 | 21,439.1 | 18,972.2 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 32,553.5 | 27,916.4 | 24,587.9 | 21,439.1 | 18,972.2 |
Other Operating Income | 90.4 | 94.7 | 81.8 | 106.1 | 75.3 |
Other Income | 1,119 | 909 | 1,092.5 | 554.7 | 339.4 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,799.5 | 92.3 | 4,31,412.42 | 564.22 | 0.89 | 4,511.27 | 99.24 |
Divis Laboratories Ltd DIVISLAB | 6,417.5 | 67.82 | 1,70,489.23 | 696 | 0.47 | 2,660 | 578.26 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,728 | 59.13 | 1,26,185.41 | 597 | 0.16 | 2,707 | 249.83 |
Cipla Ltd CIPLA | 1,516.6 | 23.57 | 1,22,510.62 | 1,210.53 | 1.05 | 4,495.16 | 411.56 |
Dr Reddys Laboratories Ltd DRREDDY | 1,275.2 | 19.73 | 1,06,522.7 | 387.3 | 0.63 | 4,602.9 | 377.56 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Co-Chairman & Managing Director
G V Prasad
Executive Chairman
K Satish Reddy
Independent Director
Shikha Sanjaya Sharma
Independent Director
Leo Puri
Independent Director
K P Krishnan
Independent Director
Pennv Wan
Company Sec. & Compli. Officer
K Randhir Singh
Independent Director
Arun M. Kumar
Independent Director
Claudio Albrecht
Independent Director
Sanjiv Mehta
Independent Director
Alpna Seth
8-2-337 Road No 3,
Banjara Hills,
Telangana - 500034
Tel: 91-40-49002900
Website: http://www.drreddys.com
Email: shares@drreddys.com; mail@drreddys.com
3rd Flr 306 Rightwin,
Amrutha Ville, Somajiguda,
Hyderabad-500082
Tel: 91-40-23374967/23370
Website: www.bigshareonline.com
Email: bsshyd@bigshareonline.com
Summary
Dr Reddys Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Phar...
Read More
Reports by Dr Reddys Laboratories Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.